Table 2 Potencies of compounds developed as Raf and Src inhibitors towards a variety of protein kinases

IC50 values were determined from assays carried out at ten different inhibitor concentrations.

CompoundProtein kinaseIC50 (μM)[ATP] in assay (μM)
SU 6656Src0.1050
Lck0.1550
Aurora B0.01920
Aurora C0.0175
BRSK20.1050
MST20.1150
AMPK0.1150
Src-I1Src0.1850
RIP20.026100
PP1Src0.05350
Lck0.04050
RIP20.026100
CK1δ0.1720
CSK0.6420
PP2Src0.03650
Lck0.03150
RIP20.019100
CK1δ0.04120
NA-PP1JNK1[M108A]0.2720
JNK1[M108G]0.6220
Src0.3450
Lck0.6650
CSK1.9720
RIP20.12100
PKD10.9050
CKI0.1520
NM-PP1JNK1[M108A]0.2520
JNK1[M108G]0.1420
Src0.6250
Lck0.4650
CSK0.5120
RIP20.13100
PKA0.5020
PKD10.2550
ZM 336372c-RAF0.031100
B-RAF0.23100
Lck0.5750
RIP2>100100
BAY 439006c-RAF0.37100
B-RAF7.3100
p38αMAPK3.2100
RIP23.6100
GW 5074c-RAF0.17100
B-RAF0.19100
PIM10.1720
PIM20.075
PIM30.1020